My issue here is that this is treating the symptoms rather than the cause. The cause is likely related in part to ACE2 scavenging. You only carry a few micrograms worth of soluble ACE2 in your blood at a time, so the virus scavenging it could significantly affect the RAS.
-
-
Replying to @nanogenomic @_RL_W and
The upside of administrating ACE2 to SARS-CoV-2 patients may be restoration of the ACE2 signaling and behavior, however the downside may be that the virus will get coated in even more ACE2 and end up having enhanced immune cloaking...
1 reply 0 retweets 2 likes -
Replying to @nanogenomic @_RL_W and
I think we need to look towards solutions that dissociate the virus from ACE2, or that create nanoscale scaffolds that don't interfere with ACE2 trafficking while displacing the virus simultaneously and allowing for ACE2 to function normally. That's causative, not a symptomatic.
1 reply 1 retweet 2 likes -
Replying to @nanogenomic @_RL_W and
The further down the chain of effects you try to treat something with, the more you are avoiding dealing with the root cause of a disease, and therefore the more severe your patients become by the very nature of the treatment...
1 reply 2 retweets 5 likes -
Replying to @nanogenomic @_RL_W and
I am also more a fan of giving just enough of a nanoscaffold to saturate soluble ACE2 and block viral entry with membrane-bound ACE2, versus the converse approach of administering ACE2-mimetics which must encounter milligrams worth of the virus and don't address immunoepitopes
5 replies 1 retweet 4 likes -
Your approach is both nuanced and sophisticated. I like the way you seduce the virus and render it ineffective simultaneously (hopefully it's as effective in practice as theory.) I'm a huge fan of nano-scaffolding, Cellular architecture and matricing FTW!
1 reply 0 retweets 1 like -
Between the structural simulations, free energy simulations, atomic resolution studies and binding studies; and the upcoming antibody pulldown studies, we will know every atom of behavior before we dose people. There is precedent now for skipping animals and it’s a peptide supp:)
3 replies 0 retweets 2 likes -
Replying to @nanogenomic @Pravduh15 and
Previously we used this same design approach to make peptides for delivering CRISPR and RNA to dozens of cellular markers and achieved best in class non-viral gene editing efficiency in human T cells...
1 reply 0 retweets 2 likes -
-
OMG i am so here for this
Andre is one of a kind.
he founded the viral explorations group I helped grow - it was one of the *key* reasons the tech community got a head start
superhuman stamina, courage & genius. have been funding this pivot since feb with my 1st profits!
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.